Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
Date:8/1/2013

ts, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on management's estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding Arena's estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or con
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, August 1
2. Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference
3. Former Semi-Pro Arena Football Player Bridged to Heart Transplant with the SynCardia Total Artificial Heart
4. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
5. BIOCOM Applauds Arena Pharmaceuticals Commitment to Innovation, Contributions to Southern California Life Science Community
6. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
7. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
8. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
9. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
10. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
11. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
(Date:5/4/2015)... 4, 2015 MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... of the Company,s investigational drug candidate ME-344 in ... combined with a tyrosine-kinase inhibitor (TKI). In addition, ... a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) ...
(Date:5/4/2015)... , May 4, 2015  Geneia, a company ... technology solutions to improve healthcare efficiencies, today announced ... Rehabilitation Center (BNRC) use Geneia,s advanced analytics ... improve the quality and lower the cost of ... clinical, outcomes, claims and utilization data from multiple ...
Breaking Medicine Technology:Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... Mylan Inc. (Nasdaq: www.mylan.com . ... release includes statements that constitute "forward-looking statements." These statements ... the Private Securities Litigation Reform Act of 1995. Because ... results may differ materially from those expressed or implied ...
... 6 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... Specialty Pharmaceuticals Conference on Thursday, August 12, 2010 , at 8:00 ... Endo, will review the company,s products and development programs. , ... The presentation will be webcast live and can ...
Cached Medicine Technology:Endo to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 Malibu ... oral antiseptic breath spray. KissSafe™ is the first ... a safer experience while adding fresh breath appeal. ... and effectively kills germs in the mouth and ... also contains ingredients that possess additional wellness benefits. ...
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a groundbreaking ceremony ... on Wednesday, April 22. , Johnson & Wales becomes the ... the re-alignment of Interstate-195. JWU’s new academic building, which will ... in Providence, is scheduled to be completed in July 2016. ... university purchased in 2012. , “It has long been our ...
(Date:5/4/2015)... The opportunity for children to dream of a ... forces behind The Fairy Godmother Next Door, a new children’s ... Stark. , The inspiration for the enchanting story of a ... Stark’s desire to be a fairy godmother. , “My wish ... my neighbors’ children since they were born. We discuss fairies ...
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3
... Increased 15%; Online Ad Revenue Increased 21%WebMD Achieves ... and 1.3 Billion Quarterly Page ViewsNEW YORK, Feb. ... WBMD ) today announced financial results for the ... results confirm WebMD,s market leadership in a challenging ...
... Feb. 19 Covance Inc. (NYSE: CVD ) ... D., to its Board of Directors. Dr. Sheares is former ... of Reliant Pharmaceuticals, Inc., a pharmaceutical company that marketed a ... was president of the U.S. Human Health division of Merck ...
... prove cause and effect, researcher says , , THURSDAY, Feb. ... fast-food joints could increase your risk for stroke by ... restaurants are less plentiful, a new study suggests. , ... known, though, said study author Dr. Lewis B. Morgenstern, ...
... Netherlands, Feb. 19 A BioPharma Pavilion at CPhI ... P-MEC Japan will be ... Japan ,s leading pharma services events by UBM International Media. ... completed by the contract services event ICSE Japan -- will be ...
... statins, used by millions of Americans to treat ... according to researchers at Texas Health Presbyterian Hospital ... the influence of statin drugs," appears in the ... make quicker, more accurate diagnoses of suspected thyroid ...
... monitoring can keep problem from advancing, experts say , , THURSDAY, ... levels causes poorer brain function in people with type 2 ... aged 55 and older at 52 sites in Canada and ... a larger study on cardiovascular risk in diabetes, underwent cognitive ...
Cached Medicine News:Health News:WebMD Announces Fourth Quarter Financial Results 2Health News:WebMD Announces Fourth Quarter Financial Results 3Health News:WebMD Announces Fourth Quarter Financial Results 4Health News:WebMD Announces Fourth Quarter Financial Results 5Health News:WebMD Announces Fourth Quarter Financial Results 6Health News:WebMD Announces Fourth Quarter Financial Results 7Health News:WebMD Announces Fourth Quarter Financial Results 8Health News:WebMD Announces Fourth Quarter Financial Results 9Health News:WebMD Announces Fourth Quarter Financial Results 10Health News:WebMD Announces Fourth Quarter Financial Results 11Health News:WebMD Announces Fourth Quarter Financial Results 12Health News:WebMD Announces Fourth Quarter Financial Results 13Health News:WebMD Announces Fourth Quarter Financial Results 14Health News:WebMD Announces Fourth Quarter Financial Results 15Health News:WebMD Announces Fourth Quarter Financial Results 16Health News:WebMD Announces Fourth Quarter Financial Results 17Health News:WebMD Announces Fourth Quarter Financial Results 18Health News:WebMD Announces Fourth Quarter Financial Results 19Health News:Covance Elects Bradley T. Sheares to Company's Board of Directors 2Health News:More Fast-Food Joints in Neighborhoods Mean More Strokes 2Health News:New Features for 2009 Japan Events 2Health News:New Features for 2009 Japan Events 3Health News:Dallas Scientists Discover Statins May Falsely Indicate Thyroid Problems 2Health News:Out-of-Control Blood Sugar May Affect Memory 2
400 Series Monopolar Foot Activated Forceps...
Dissecting Forceps, straight, with RF-cable, 7" (18 cm). For use with all electrosurgical generators with standard three-prong sockets....
Extended blade - 25/box....
... In the way it implements the ... 510 Meta system is unmatched. It allows ... compromising resolution and efficiency. Unprecedented flexibility for ... functions that guarantee fast and efficient structural ...
Medicine Products: